Source comparison
BPC-157 Cartalax Joint Research: Comparison of Mechanisms
BPC-157 VEGF receptor-2 upregulation, FAK pathway activation, angiogenesis promotion Tendons, ligaments, vascular endothelium 24–48 hours (vascular changes detectable) 4–6 hours Daily Best suited for injury models where vascular insufficiency limits healing. L
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF receptor-2 upregulation, FAK pathway activation, angiogenesis promotion
- Tendons, ligaments, vascular endothelium
- 24–48 hours (vascular changes detectable)
- 4–6 hours
- Daily
- Best suited for injury models where vascular insufficiency limits healing. Ligament tears, tendon injuries, ischaemic tissue
- Cartalax
- Chromatin modulation, COL2A1 and ACAN gene upregulation, chondrocyte transcriptional regulation
- Articular cartilage, chondrocytes
- 48–96 hours (gene expression changes)
- Not definitively established; effects persist 72–96 hours post-dose
- Every 48–72 hours
- Optimal for cartilage degradation models and age-related matrix loss. Osteoarthritis models, chondrocyte senescence studies
- Combined Protocol
- Additive: vascular repair + cartilage matrix synthesis
- Multi-tissue joint structures (ligament + cartilage)
- 48–72 hours (combined effects)
- Mixed (requires daily BPC-157, every-other-day Cartalax)
- BPC-157 daily, Cartalax every 48 hours
- Appropriate for complex joint injury models involving both soft tissue and cartilage damage. ACL reconstruction, meniscal repair, post-traumatic osteoarthritis